Back to Newsroom
Back to Newsroom

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Karyopharm Therapeutics Inc. (KPTI) Investigation

Thursday, January 19, 2023 12:35 PM
Bronstein, Gewirtz and Grossman, LLC

NEW YORK, NY / ACCESSWIRE / January 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI). Investors who purchased Karyopharm securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:

Bronstein, Gewirtz and Grossman, LLC, Thursday, January 19, 2023, Press release picture

The investigation concerns whether Karyopharm has violated federal securities laws.

On February 8, 2022, Karyopharm reported "successful"-though ultimately disappointing-results from its Phase 3 SIENDO Study of Xpovio for the treatment of endometrial cancer. Specifically, the treatment reduced patients' risk of disease progression or death by 30%, just barely enough to be considered statistically significant, and median progression-free survival was just 5.7 months compared to 3.8 months among patients randomized to receive a placebo. On this news, Karyopharm's stock price fell $2.05 per share, or 20.02%, to close at $8.19 per share on February 8, 2022.

Then, on March 1, 2022, Karyopharm reported negative feedback from the U.S. Food and Drug Administration ("FDA") on its supplemental NDA for Xpovio based on the Phase 3 SIENDO Study results for endometrial cancer. Specifically, the FDA found that the current results would not support NDA approval as Karyopharm and the FDA participants had differing views on the study's significance and overall clinical benefit for the whole population. On this news, Karyopharm's stock price fell $4.13 per share, or 39.75%, to close at $6.26 per share on March 2, 2022.

If you are aware of any facts relating to this investigation or purchasedKaryopharm shares, you can assist this investigation by visiting the firm's site: You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Class Action
Back to newsroom
Back to Newsroom